Indovazin - instructions for use, dose, side effects, contraindications

Active substanceIndomethacin + TroxerutinIndomethacin + Troxerutin

Similar drugsTo uncover

Indovazin®

gel externally

Balkanfarm - Troyan AD Bulgaria

Trixymethacin

gel externally

VetProm AD Bulgaria

Dosage form: & nbspgel for external use

Composition:

100 grams of gel for external use contain:

Active substances:

Indomethacin 3.0 g,

Troxerutin 2.0 g;

Excipients:

Carbomer 2.00 g Disodium edetate 0.05 g Sodium benzoate 0.25 g, 40.00 g Macrogol 400, isopropanol, 20.00 g, 15.00 g of dimethyl sulfoxide, flavoring Fresco BM & GD R.08.0932.1 0,20 g, purified water up to 100 g.

Description:Gel from yellow to yellow-brown color with a slight opalescence.

Pharmacotherapeutic group:Anti-inflammatory agent for topical application

ATX: & nbsp

M.01.A.B.51 Indomethacin in combination with other drugs

Pharmacodynamics:

Indovazin® gel is a combined drug, which comprises indomethacin and troxerutin.

Indomethacin has a pronounced anti-inflammatory, analgesic and anti-edematous effect. This leads to the removal of pain, reducing edema and reducing the recovery time of damaged tissues. The main mechanism of action is associated with the suppression of the synthesis of prostaglandins through a reversible blockade of cyclooxygenase 1 and 2.

Troxerutin (trihydroxyethylrutinoside) is a bioflavonoid. It refers to angioprotective agents. Reduces the permeability of capillaries and exhibits a venotonic effect. It blocks the venodilating effect of histamine, bradykinin and acetylcholine. It acts anti-inflammatory on perennial tissue, reduces the fragility of capillaries and has some antiaggregant effect.

Reduces puffiness, improves trophic with pathological changes associated with venous insufficiency.

When applied to the skin, Indovazin® gel suppresses the inflammatory edematous reaction, relieves pain and temperature in the inflammatory foci, located on the surface and in the depth, reaching the blood vessels located there. It exhibits venotonic and capillaroprotective action.

Pharmacokinetics:

The used ointment base ensures the solubility and release of drugs Indomethacin and Troxerutin. The gel dosage form, which includes indomethacin and troxerutin, is well absorbed from the surface of the skin and provides a therapeutic effect of the drug.

When applied to the skin in the subcutaneous tissue and periarticular tissues, concentrations close to therapeutic are created. The penetration of active components of the drug into the systemic blood flow is clinically insignificant.

Indications:

- In complex therapy of chronic venous insufficiency of the lower extremities (varicose veins) - to relieve edema, feelings of heaviness and pain in the legs;

- superficial thrombophlebitis, phlebitis; postflebit states;

- rheumatic damage of soft tissues: tendovaginitis, bursitis, fibrositis, periarthritis;

- with swelling after surgical interventions, contusions, dislocations, sprains.

Contraindications:

- Hypersensitivity to the components of the drug;

- hypersensitivity to NSAIDs (non-steroidal anti-inflammatory drugs);

- III trimester of pregnancy and lactation;

- children under 14 years of age (no clinical experience of use);

- violation of the integrity of the skin.

Carefully:

Simultaneous reception of the drug with other NSAIDs, bronchial asthma, allergic rhinitis, polyps of the nasal mucosa.

Pregnancy and lactation:

Clinical experience proving the safety of the drug when used during pregnancy and lactation,absent. Its use is possible only if the expected benefit exceeds the potential risk to the fetus.

Dosing and Administration:

The drug is intended for external use.

4-5 cm of gel is applied 3-4 times a day with a thin layer on the affected area with light rubbing movements. The total daily amount should not exceed 20 cm. The duration of treatment should not exceed 10 days.

Side effects:

Drug tolerance is usually good.

Local Reactions: there may be symptoms of increased hskin sensitivity - contact dermatitis, itching, redness, rash, a feeling of heat and burning in the place of application.

Overdose:

There is no information about cases of overdose with topical application.

If you accidentally swallow large amounts of possible burning sensation in the mouth, salivation, nausea, vomiting.

The measures to be taken in this case are washing the oral cavity and stomach, if necessary, symptomatic treatment.

Interaction:

Ointment can enhance the effect of drugs that cause photosensitivity.

Clinically significant interaction with other drugs is not described.

Special instructions:

Do not apply to open wounds, mucous membranes, into the mouth, eyes.

After applying the drug, do not apply an occlusive bandage.

In case of contact with eyes, mucous membranes or open wound surfaces, local irritation is observed - tearing, redness, burning, pain.

The necessary measures - washing the affected area with a copious amount of water or saline until the complaints disappear or decrease.

The indovazin® gel contains sodium benzoate and dimethylsulfoxide as auxiliary substances, which can have irritating effect on the skin.

If you notice any side effects or unusual reactions, you should consult your doctor about further treatment.

Effect on the ability to drive transp. cf. and fur:

Does not affect the speed of psychomotor reactions when driving and working with mechanisms.

Form release / dosage:Gel for external use.

Packaging:

For 45 g of the drug in an aluminum tube.

Each tube together with the instruction for use is placed in a cardboard box.

Storage conditions:

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date stated on the package.

Terms of leave from pharmacies:Without recipe

Registration number:П N012746 / 01

Date of registration:14.08.2008 / 10.01.2017

Expiration Date:Unlimited

The owner of the registration certificate:Balkanfarm - Troyan ADBalkanfarm - Troyan AD Bulgaria

Manufacturer: & nbsp

BALKANPHARMA-TROYAN, AD Bulgaria

Representation: & nbspAktavis, Open Company Aktavis, Open Company

Information update date: & nbsp31.10.2017

Illustrated instructions

Instructions

Indovazin® (Indovasin®)